CN1628660A - Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract - Google Patents
Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract Download PDFInfo
- Publication number
- CN1628660A CN1628660A CN 200410040648 CN200410040648A CN1628660A CN 1628660 A CN1628660 A CN 1628660A CN 200410040648 CN200410040648 CN 200410040648 CN 200410040648 A CN200410040648 A CN 200410040648A CN 1628660 A CN1628660 A CN 1628660A
- Authority
- CN
- China
- Prior art keywords
- fibrauretin
- adjuvant
- percentage
- liquid preparation
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is externally used fibrauretine liquid for gynaecology and oral cavity, wherein the preparation essentially comprises fibrauretine as active constituent, and balancing adjuvant and water for preparing the externally used liquid preparation, the fibrauretine is alkaloid extracted from natural plant of fibraurea stem, calculated by dried product, it comprises Palmatine Hydrochloride C21H21O.HCl 20-98%. The dosage type includes externally used liquid lotion or liniment, foam aerosol, ointment, gargle or spray.
Description
Technical field
The present invention relates to a kind of liquid preparation for external application such as gynecological, the department of stomatology of fibrauretin, particularly relate to a kind of fibrauretin and wash (wiping) agent, foam aerosol, ointment, collutory, spray.
Background technology
Candida albicans belongs to Candida, claim saccharomyces albicans again, cultivate the back microscopy, as seen oval blastogenesis cell and pseudohypha, it is a kind of conditioned pathogen, usually be present on normal person's oral cavity, upper respiratory tract and the genitals vaginal mucosa, when body's immunity reduce or the microorganism of normally living away from home between mutual restriction effect imbalance cause candidiasis easily.
Candida albicans infection has increased more than 20 times over nearly 20 years, has become one of major causes of death of hospital infection.Particularly nearly 10 years, Candida albicans shared ratio in pathogenic bacterium rose day by day.Reports such as Wu Shaoxi: 9139 strain pathomycetes and isolated 18085 strain pathomycetes in 1996 that 41 representative units of 25 provinces of China (comprising China Taiwan Province) were collected in 1985, find Candida albicans from the 5th the 2nd of rising to 1996 in 1986, shared ratio from 1986 5% rise to 1996 196%.This proves absolutely that Candida albicans has become important pathogen.
Gynaecopathia such as vaginitis, cervicitis is that invasive organism enters the local infection that causes in the reproductive tract by vaginal opening.The strong center of the woman of Peking University First Hospital children's health care carries out to Beijing, Zhengzhou, Nanning, 2002 the unmarried artificial abortion women below 24 years old in four cities, Shenzhen that the survey showed that, has 1144 people to suffer from reproductive tract infection, and prevalence is 57.1%.Investigation to 264 routine vaginal infection shows that the Candida albicans vaginitis mainly concentrates in the middle-aged women, and the city women is more than rural women.This may with too much application antibiotic and the topical antibiotic of city women, the gram-negative bacteria that make to produce the anti-candida material is suppressed, and has destroyed the symbiotic environment of normal flora, has helped the Candida albicans breeding.About 10% healthy women and 30% anemia of pregnant woman can not have any symptom and intravaginal has Candida albicans.Male's Candida albicans balanitis is to infect by sexual intercourse mostly, report is arranged and suffer from the sexual male who contacts of candida albicans vaginitis women, its genitals is infected to reach 69.4%, with the sexual women's generation contact that contacts of Candida albicans balanitis male, candida albicans vaginitis is up to 80%.
The Wang Ya of Zhejiang Provincial People's Hospital rosy clouds report, 1～December, 149 routine Candida albicans caused the hospital infection patient in 2002, the oral mucosa infection rate is 19.4%.
In recent ten years, host immune is impaired etc. to cause fungus-caused clinically infection to be obvious ascendant trend because the abuse of clinical immunosuppressant, extensive pedigree antibiotic and some factor make.Increasing of fungal infection rate promotes the exploitation of antifungal drug and clinically widely-used, causes the generation of persister again.Because azole drug has advantages such as anti-fungus spectra is wide, oral absorption is good, thereby the extremely clinicist's favor of such medicine, clinical practice at present is more, and frequently uses antifungal drug, cause the increase of Resistant strain again, particularly outstanding to the drug resistance phenomenon of azole drug.Bibliographical information, 102 strains are tried bacterium the resistant rate of fluconazol and itraconazole are reached 8.8% and 11.8% respectively.During the clotrimazole low concentration only part suppress the synthetic of ergosterol, then suppress fully during high concentration and present powerful bactericidal action, and the generation of the easy inducible resistance bacterial strain of high concentration administration.Though the responsive rate of flucytosine is up to 100%, the same with amphotericin B, ketoconazole, human body is had bigger toxicity, limited such medicine in clinical use.
The untoward reaction of antifungal chemistry medicine can not be ignored, and according to the report of the international medicine of WHO monitoring center, in July, 1987, has received untoward reaction 1285 examples due to various countries' report ketoconazole, causes liver injury 361 examples.The report of China's Ministry of Public Health and Beijing's drug surveilance office from November, 1987 to 1991 year JIUYUE, has been received serious liver injury 16 examples due to each tame hospital report ketoconazole of Beijing, and wherein 4 examples are died after ineffectual treatment.The untoward reaction that fluconazol is general has that headache, inappetence, liver transaminase raise, feel sick, vomiting, alopecia, erythra, gastrointestinal reaction etc.; but some special untoward reaction also appear, as: serious mental symptom, the heart interface rhythm of the heart, the ventricular premature contraction that takes place frequently, QT interval prolongation and tachycardia, peripheral neuritis, Addison's disease crisis etc.In the article of curative effective of Itraconazole in curing fungal infection, the case that safety report arranged is totally 14725 examples, and that main adverse reaction has is nauseating, epigastric discomfort inappetence, anorexia, stomachache, dizziness, give birth to that skin ulcer, epistaxis blood, uncomfortable in chest, skin pruritus, appetite increase, headache, xerostomia, asymptomatic transaminase slightly raise, facial edema.
Candida albicans causes that the untoward reaction of increasing day by day of infection and antifungal chemicals and drug resistance have become the world of medicine's problem anxious to be solved, screen novel, safe, anti-candida albicans medicine efficiently, particularly natural plant is just becoming the developing direction that present antifungal drug is studied.
The total alkaloids that extracts in the Caulis Fibraureae prime system Radix Stephaniae Tetrandrae section plant Caulis Fibraureae plants such as (Fibraurea recisa) mainly contains palm leaf Radix Stephaniae Tetrandrae alkali (having another name called: palmatine Palmatine, palmatine, African Radix Stephaniae Tetrandrae alkali), and its chloride is yellow acicular crystal, and flavor is extremely bitter.Clinical gynecological inflammation, bacillary dysentery, enteritis, respiratory tract and urinary tract infection, surgical infection, the eye conjunctivitis of can be used for of Caulis Fibraureae.There is report to treat surgical infection, gynecological inflammation, bacillary dysentery, gastroenteritis, respiratory tract and urinary tract infection with Caulis Fibraureae, example surplus the eye conjunctiva light etc. 1500, evident in efficacy.Fibrauretin is 500 μ g/ml to the inhibition concentration of staphylococcus aureus and Sabouraudites lanosus, is 250 μ g/ml to the oidiomycetic inhibition concentration of white.
Existing fibrauretin preparation is injection and tablet, suppository etc., though treatment gynecological and oral cavity infection are effective, there is the manufacturing condition harshness in injection, uses shortcomings such as inconvenient, that the focus local drug concentration is low, the course of treatment long, patient's compliance is poor, side effect is many; Oral tablet exists that dosage is big, gastrointestinal irritation, easily cause shortcomings such as alteration of intestinal flora, onset is slow, bioavailability is low, the course of treatment is long, the focus local drug concentration is low; Though suppository directly acts on pathogenic position, but use inconvenience, easily contaminated, a large amount of substrate to influence pharmaceutically-active degree and release, can moisture absorption when ambient temperature is too high and adhere, often easily dehydration and become fragile, become broken, distortion, variable color, adhesion, thawing, the influence use again when drying.
Summary of the invention
Purpose of the present invention mainly is the anti-candida albicans deficiency at existing chemical medicine, crude drug technology, invent a kind of liquid preparation for external application that contains fibrauretin, it is directly used in reproductive tract, oral cavity and the respiratory tract, in the mode of topical, directly acts on disease position or absorption site.Compare with injection with oral, medicine is not subjected to the destruction of gastrointestinal PH or enzyme, the destruction of liver first-pass effect in the time of can avoiding oral administration, reduce the influence of medicine to liver, human body is disturbed few, in addition, topical can significantly reduce dosage, improves the focus local drug concentration, reduces toxicity and improve patient's compliance.
Technical scheme of the present invention is: a kind of liquid preparation for external application that contains fibrauretin, and it is waited to levy and is that the effective ingredient that said preparation essence contains is a fibrauretin, and surplus is for making the adjuvant and the water of liquid preparation for external application; Wherein fibrauretin by dry product, contains anhydrous palm leaf Radix Stephaniae Tetrandrae alkali (hydrochloride Palmatine C for extract the total alkaloids that obtains from the Caulis Fibraureae natural plants
21H
21O
4N.HCl) 20～98%.Dosage form is that external use liquid is washed (wiping) agent, foam aerosol, ointment, collutory or spray; Liquid in the described fibrauretin liquid preparation for external application is washed (wiping) agent, it is characterized in that having of one's own with the arbitrary proportion that contains medicinal adjuvant 99.90～50.01% (percentage by weight) by containing fibrauretin 0.10～49.99% (percentage by weight).Foam aerosol in the described fibrauretin liquid preparation for external application is characterized in that containing effective fibrauretin 0.10～49.99%, and its surplus is adjuvant solvent, emulsifying agent, propellant, and adjuvant contains 99.90～50.01% (percentage by weights) altogether.Ointment in the described fibrauretin liquid preparation for external application is characterized in that containing effective fibrauretin 0.10～49.99%, and its surplus is adjuvant solvent, emulsifying agent, and adjuvant contains 99.90～50.01% (percentage by weights) altogether.Collutory in the described fibrauretin liquid preparation for external application is characterized in that containing effective fibrauretin 0.1～50.01% (percentage by weight), and its surplus is that adjuvant is solvent, correctives, total 99.99～50.01% (percentage by weights) that contain of adjuvant.Spray in the described fibrauretin liquid preparation for external application is characterized in that containing effective fibrauretin 0.1～50.01% (percentage by weight), and its surplus adjuvant is solvent, correctives, total 99.99～50.01% (percentage by weights) that contain of adjuvant.
The purposes that the present invention contains the fibrauretin liquid preparation for external application is the Candida albicans of eliminating or eliminating in reproductive tract, oral cavity and the upper respiratory tract.
The used solvent of the present invention is water, ethanol, Polyethylene Glycol, 1,2-propylene glycol, ethylene glycol.
The used emulsifying agent of the present invention is tween 80, polyoxyethylene alkyl ether, sodium stearyl sulfate.
The used substrate of the present invention is glycerin gelatine, sodium carboxymethyl cellulose, carbopol, Polyethylene Glycol.
The used propellant of the present invention is dichlorodifluoromethane, Dichloromonofluoromethane, F-22, dichlorotetra-fluoroethane, a chloropentafluoroethane, chlorodifluoroethane, Difluoroethane, trichorotrifluoroethane.
The used correctives of the present invention is Folium Caryophylli oil, Oleum menthae, rose absolute, jasmine flower essence, Mel, sucrose, saccharin sodium.
The present invention washes (wiping) agent, foam aerosol, spray with what fibrauretin made that vagina and oral cavity partial use, collutory, ointment, have that dosage is little, rapid-action, (for example: the intravaginal local concentration when washing liquid is used is 20mg/ml to focus local drug concentration height, be 64 times of Candida albicans MIC, can kill Candida albicans rapidly), toxicity is little, production cost is low, easy to use, advantage such as patient's compliance is good.Compare with suppository, foam aerosol and spray are uniformly dispersed in vaginal canal, are coated with widely, and medicine can effectively infiltrate mucosal fold, does not influence the normal pH value of vagina cleanness degree and vaginal content, can obtain excellent curative.
Specific embodiments
By specific embodiment given below and experimental data material, can further be well understood to liquid preparation for external application of the present invention and uses thereof.But they are not limitation of the invention.
Embodiment 1 fibrauretin liquid is washed the embodiment of (wiping) agent
1. write out a prescription (every 100ml consumption)
Fibrauretin 0.1g (0.1%)
Sterilized water 99.9g (99.9%)
2. method for making: the fibrauretin of the consumption of will writing out a prescription is soluble in water, mixing.
Embodiment 2 fibrauretin liquid are washed the embodiment of (wiping) agent
1. write out a prescription (every 100ml consumption)
Fibrauretin 2g (2.0%)
Sterilized water 98g (98.0%)
2. method for making: the fibrauretin of the consumption of will writing out a prescription is soluble in water, mixing.
Embodiment 3 fibrauretin liquid are washed the embodiment of (wiping) agent
1. write out a prescription (every 100ml consumption)
Fibrauretin 49.99g (49.99%)
Sterilized water 50.01g (50.01%)
2. will the write out a prescription fibrauretin of consumption of method for making is soluble in water, mixing.
Embodiment 4 fibrauretin ointment embodiments
1. fill a prescription
Fibrauretin 0.1g (0.1%)
Gelatin 3.0g (3.0%)
Glycerol 30.0g (30.0%)
Water 66.9g (66.9%)
2. method for making: each supplementary material weighing of the consumption of will filling a prescription, dissolve packing behind the mixing, packing.
Embodiment 5 fibrauretin ointment embodiments
1. fill a prescription
Fibrauretin 49.9g (49.9%)
Macrogol 4000 10.0g (10.0%)
PEG400 30.0g (30.0%)
Water 10.1g (10.1%)
2. method for making: each supplementary material weighing of the consumption of will filling a prescription, dissolve packing behind the mixing, packing.
Embodiment 6 fibrauretin ointment embodiments
1. fill a prescription
Fibrauretin 2.0g (2.0%)
Carbopol 940 10.0g (10.0%)
Ethanol 5.0g (5.0%)
Glycerol 5.0g (5.0%)
Water 88.0g (88.0%)
2. method for making: each supplementary material weighing of the consumption of will filling a prescription, dissolve packing behind the mixing, packing.
Embodiment 7 fibrauretin collutory embodiments
1. fill a prescription
Fibrauretin 0.1g (0.1%)
Water 99.9g (99.85%)
Oleum menthae 0.05g (0.05%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
Embodiment 8 fibrauretin collutory embodiments
1. fill a prescription
Fibrauretin 49.9g (49.9%)
Water 50.1g (50.05%)
Oleum Rosae Rugosae 0.05g (0.05%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
Embodiment 9 fibrauretin collutory embodiments
1. fill a prescription
Fibrauretin 2.0g (2.0%)
Water 98.0g (97.95%)
Oleum Caryophylli 0.05g (0.05%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
Embodiment 10 fibrauretin foam aerosol embodiments
1. fill a prescription
Fibrauretin 0.1g (0.1%)
1,2-propylene glycol 10.4g (10.4%)
Ethylene glycol 16.7g (16.7%)
Dichlorodifluoromethane (F
12) 7.0g (7.0%)
Distilled water 65.8g (65.8%)
2. method for making: except that dichlorodifluoromethane, will fill a prescription each supplementary material weighing, dissolving, packing pour into dichlorodifluoromethane, promptly at last.
Embodiment 11 fibrauretin foam aerosol embodiments
1. fill a prescription
Fibrauretin 49.9g (49.9%)
1,2-propylene glycol 10.4g (10.4%)
Ethylene glycol 16.7g (16.7%)
Dichlorodifluoromethane (F
12) 7.0g (7.0%)
Distilled water 15.5g (15.5%)
2. method for making: except that dichlorodifluoromethane, will fill a prescription each supplementary material weighing, dissolving, packing pour into dichlorodifluoromethane, promptly at last.
Embodiment 12 fibrauretin foam aerosol embodiments
1. fill a prescription
Fibrauretin 2.0g (2.0%)
1,2-propylene glycol 10.4g (10.4%)
Ethylene glycol 16.7g (16.7%)
Dichlorodifluoromethane (F
12) 7.0g (7.0%)
Distilled water 63.9g (63.9%)
2. method for making: except that dichlorodifluoromethane, will fill a prescription each supplementary material weighing, dissolving, packing pour into dichlorodifluoromethane, promptly at last.
Embodiment 13 fibrauretin spray embodiments
1. fill a prescription
Fibrauretin 0.1g (0.1%)
Sterilized water 99.9g (99.9%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
Embodiment 14 fibrauretin spray embodiments
1. fill a prescription
Fibrauretin 49.9g (49.9%)
Sterilized water 50.1g (50.1%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
Embodiment 15 fibrauretin spray embodiments
1. fill a prescription
Fibrauretin 2g (2.0%)
Sterilized water 98 (98.0%)
2. method for making: will fill a prescription each supplementary material weighing, dissolving, mixing.
The extracorporeal bacteria inhibitor test material of fibrauretin series of products of the present invention is as follows:
1. be subjected to the reagent thing
The fibrauretin spray, lot number: 20040601; Become to contain the test liquid of principal agent 10mg/ml with dissolved in distilled water.
The fibrauretin collutory, lot number: 20040602; Become to contain the test liquid of principal agent 10mg/ml with dissolved in distilled water.
The fibrauretin washing liquid, lot number: 20040603; Contain principal agent 10mg/ml, with stock solution as test liquid.
The fibrauretin foam aerosol, lot number: 20040604; Contain principal agent 7.5mg/ml, with stock solution as test liquid.
Above test liquid is provided by Kunming wild camellia Science and Technology Ltd..It is standby to test preposition 8 pounds of 30 minutes autoclavings.
2. for the examination culture medium: Nutrient agar, nutrient broth, husky guarantor Ruo Shi culture medium, calf serum are provided by Shanghai Vaccine and Serum Institute, and fresh sheep blood is provided by animal section of unming Medical College.Standby behind the conventional preparation autoclaving.
3. for recovery of examination strain and preparation: escherichia coli CMCC (B) 44103; Staphylococcus aureus CMCC (B) 26003; Candida albicans CMCC (F) 98001; Above strain is preserved by microorganism teaching and research room of unming Medical College.After the reference culture of above-mentioned cold moving kept dry recovered in the corresponding liquid culture medium, escherichia coli, staphylococcus aureus transferred species were cultivated 24 hours for 37 ℃ to nutrient agar panel, blood agar plate; The Candida albicans transferred species is accompanied on the base to Sha Shi, hatches 48 hours for 37 ℃.Take out the single bacterium colony of back picking with the range estimation of physiological saline solution dilution reuse McFarLand standard opacity tube than turbid be 3 * 10
5Cfu/ml is standby.
Method
Adopt the test tube double dilution method to measure the MIC of test liquid to above-mentioned strain.
The adding of the dilution of medicinal liquid and bacterium liquid sees Table 1.
The adding of the dilution of table 1 medicine and bacterium liquid
| Test tube number | 1?????2?????3?????4??????5??????6??????7???????8???????9?????10 |
| Culture fluid (ml) | 1.0?}?1.0?}?1.0?}?1.0??}?1.0??}?1.0??}?1.0???}?1.0???}?1.0?}?1.0?} |
| Medicinal liquid (ml) | 1.0???1.0???1.0???1.0????1.0????1.0????1.0?????1.0?????1.0???0 |
| The medicinal liquid dilution factor | Medicine was right to bacterium in 1: 21: 41: 81: 16 1: 32 1: 64 1: 128 1: 256 |
| Bacterium liquid (ml) | 0.1???0.1???0.1???0.1????0.1????0.1????0.1?????0.1?????0?????0.1 |
Attention: the 9th pipe only adds medicine and does not add antibacterial for the medicine contrast, whether mainly observes medicine by living contaminants; The 10th pipe only adds antibacterial and does not add medicine for the antibacterial contrast, mainly observes antibacterial growing state under the same conditions.
After pressing table 1 operation, escherichia coli, staphylococcus aureus are put 37 ℃ and cultivate the corresponding flat board of liquid transferred species that 24 hours (because of the bad observation of the influence of medicine pigment) get in each test tube once more and cultivate, sabouraud culture medium is put into the inclined-plane after adding medicine, and cooling back adding bacterium liquid 0.1ml on the inclined-plane puts 37 ℃ of cultivations and took out observed result in 48 hours.
Everyly contain that medicine least concentration pipe antibacterial is repressed to be the minimal inhibitory concentration of this medicine (MIC).The growing state of antibacterial in each test tube sees Table 2.
The result
Result of the test (table 3) shows:
1, the fibrauretin spray is that the medicinal liquid that dilutes at 1: 2 is 5mg/ml to colibacillary MIC; MIC to staphylococcus aureus is that the medicinal liquid that dilutes at 1: 8 is 1.25mg/ml; To the oidiomycetic MIC of white is that the medicinal liquid that dilutes at 1: 16 is 0.625mg/ml.
2, the fibrauretin collutory is that the medicinal liquid that dilutes at 1: 8 is 1.25mg/ml to colibacillary MIC; MIC to staphylococcus aureus is that the medicinal liquid that dilutes at 1: 16 is 0.625mg/ml, is that the medicinal liquid that dilutes at 1: 64 is 0.156mg/ml to the oidiomycetic MIC of white.
Table 2 contains bacterial growth situation in each test tube of test liquid
| Test tube numbers 123456789 10 |
| Fibrauretine spray Escherichia coli-+++++++-+staphylococcus aureus---+++++-+Candida albicans---++++-+fibrauretine gargle Escherichia coli---+++++-+staphylococcus aureus---++++-+Candida albicans------++-+fibrauretine washing lotion Escherichia coli--++++++-+staphylococcus aureus---+++++-+Candida albicans-----+++-+fibrauretine foam aerosol Escherichia coli--++++++-+staphylococcus aureus---++++-+Candida albicans-----+++-+ |
Annotate :+for bacterial growth is arranged ,-be no bacterial growth.
Table 3 fibrauretin series of products are to the minimum inhibitory concentration (mg/ml) of common vaginal pathogenic
| Escherichia coli | Staphylococcus aureus | Candida albicans | |
| The fibrauretin spray | ????5.00 | ????1.25 | ????0.625 |
| The fibrauretin collutory | ????1.25 | ????0.625 | ????0.156 |
| The fibrauretin washing liquid | ????2.50 | ????1.25 | ????0.31 |
| The fibrauretin foam aerosol | ????1.88 | ????0.47 | ????0.23 |
3, the fibrauretin washing liquid is that the medicinal liquid that dilutes at 1: 4 is 2.5mg/ml to colibacillary MIC; MIC to staphylococcus aureus is that the medicinal liquid that dilutes at 1: 8 is 1.25mg/ml; To the oidiomycetic MIC of white is that the medicinal liquid that dilutes at 1: 32 is 0.31mg/ml.
4, the fibrauretin foam aerosol is that the medicinal liquid that dilutes at 1: 4 is 1.88mg/ml to colibacillary MIC; MIC to staphylococcus aureus is that the medicinal liquid that dilutes at 1: 16 is 0.47mg/ml, is that the medicinal liquid that dilutes at 1: 32 is 0.23mg/ml to the oidiomycetic MIC of white.
The in vitro tests that the present invention carries out shows that the fibrauretin spray is respectively 5mg/ml to the MIC of escherichia coli, staphylococcus aureus, Candida albicans; 1.25mg/ml; 0.625mg/ml.The fibrauretin collutory is respectively 1.25mg/ml to the MIC of escherichia coli, staphylococcus aureus, Candida albicans; 0.625mg/ml; 0.156mg/ml.The fibrauretin washing liquid is respectively 2.5mg/ml to the MIC of escherichia coli, staphylococcus aureus, Candida albicans; 1.25mg/ml; 0.31mg/ml.The fibrauretin foam aerosol is respectively 1.88mg/ml to the MIC of escherichia coli, staphylococcus aureus, Candida albicans; 0.47mg/ml; 0.23mg/ml.Wherein, collutory, foam aerosol show that to the 250 μ g/ml that the oidiomycetic MIC of white is lower than bibliographical information the change of preparation technique condition can improve the anti-candida albicans effect of fibrauretin.
Claims (9)
1, a kind of liquid preparation for external application that contains fibrauretin is characterized in that the effective ingredient that contains in the preparation is a fibrauretin, and its surplus is for making the adjuvant and the water of external preparation.
2, a kind of liquid preparation for external application that contains fibrauretin according to claim 1 is characterized in that: fibrauretin by dry product, contains anhydrous palm leaf Radix Stephaniae Tetrandrae alkali (hydrochloride Palmatine C for extract the total alkaloids that obtains from the Caulis Fibraureae natural plants
21H
21O
4N.HCl) 20～98%.
3, a kind of liquid preparation for external application that contains fibrauretin according to claim 1 and 2, the dosage form that it is characterized in that said preparation are that external use liquid is washed (wiping) agent, foam aerosol, ointment, collutory or spray.
4, wash (wiping) agent according to the liquid in the described fibrauretin liquid preparation for external application of claim 3, it is characterized in that and to have of one's own with the arbitrary proportion that contains medicinal solvent 99.90～50.01% (percentage by weight) by containing fibrauretin 0.10～49.99% (percentage by weight).
5, according to the foam aerosol in the described fibrauretin liquid preparation for external application of claim 3, it is characterized in that containing effective fibrauretin 0.10～49.99%, its surplus is adjuvant solvent, emulsifying agent, propellant, and adjuvant contains 99.90～50.01% (percentage by weights) altogether.
6, according to the ointment in the described fibrauretin liquid preparation for external application of claim 3, it is characterized in that containing effective fibrauretin 0.10～49.99%, its surplus is adjuvant solvent, emulsifying agent, and adjuvant contains 99.90～50.01% (percentage by weights) altogether.
7, fibrauretin collutory according to claim 3 is characterized in that containing effective fibrauretin 0.1～50.01% (percentage by weight), and its surplus is that adjuvant is solvent, correctives, total 99.99～50.01% (percentage by weights) that contain of adjuvant.
8, fibrauretin spray according to claim 3 is characterized in that containing effective fibrauretin 0.1～50.01% (percentage by weight), and its surplus adjuvant is solvent, correctives, total 99.99～50.01% (percentage by weights) that contain of adjuvant.
9, the purposes that contains the fibrauretin liquid preparation for external application according to claim 1 is characterized in that being used for eliminating the Candida albicans of reproductive tract, oral cavity and upper respiratory tract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040648 CN1269479C (en) | 2004-09-06 | 2004-09-06 | Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040648 CN1269479C (en) | 2004-09-06 | 2004-09-06 | Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1628660A true CN1628660A (en) | 2005-06-22 |
| CN1269479C CN1269479C (en) | 2006-08-16 |
Family
ID=34845846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410040648 Expired - Fee Related CN1269479C (en) | 2004-09-06 | 2004-09-06 | Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1269479C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908306A (en) * | 2012-11-13 | 2013-02-06 | 河南亚卫动物药业有限公司 | Fibrauretine external preparation for beasts and birds and preparation method thereof |
| CN102908348A (en) * | 2012-09-18 | 2013-02-06 | 湖南中医药大学 | Application of sinomenine hydrochloride on treatment of male anti-sperm antibody positive immunological infertility |
| CN104055734A (en) * | 2014-06-23 | 2014-09-24 | 西安医学院 | Traditional Chinese medicinal composition for treating vaginitis and preparation method of foam aerosol thereof |
-
2004
- 2004-09-06 CN CN 200410040648 patent/CN1269479C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908348A (en) * | 2012-09-18 | 2013-02-06 | 湖南中医药大学 | Application of sinomenine hydrochloride on treatment of male anti-sperm antibody positive immunological infertility |
| CN102908348B (en) * | 2012-09-18 | 2014-02-12 | 湖南中医药大学 | Application of sinomenine hydrochloride on treatment of male anti-sperm antibody positive immunological infertility |
| CN102908306A (en) * | 2012-11-13 | 2013-02-06 | 河南亚卫动物药业有限公司 | Fibrauretine external preparation for beasts and birds and preparation method thereof |
| CN104055734A (en) * | 2014-06-23 | 2014-09-24 | 西安医学院 | Traditional Chinese medicinal composition for treating vaginitis and preparation method of foam aerosol thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1269479C (en) | 2006-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1679888A (en) | Decoction Chinese medicine sterilizing antiphlogistic, preparation and use thereof | |
| CN1872235A (en) | Muskiness acesodyne ointment of chasing wind, and preparation method | |
| CN1269479C (en) | Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract | |
| CN1583088A (en) | Vaginal effervescent tablets for woman inflammation and their preparation | |
| CN102743663A (en) | Chinese medicinal preparation for treating urinary infection and preparation method thereof | |
| CN103272092A (en) | Huoxiang Zhengqi externally-applied preparation and its preparation method and application | |
| CN107213142A (en) | The application of oxidized resveratrol or oxidized resveratrol joint antibiotic in anti-fungal infection product is prepared | |
| CN106668331A (en) | Composition having functions of diminishing inflammation, inhibiting bacteria and promoting wound healing and preparation method thereof | |
| CN109771595A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gynaecological imflammation | |
| CN106177900B (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN1202233C (en) | Compound lotion detergent for cleaning and sterilizing and its preparing method | |
| CN100569277C (en) | A kind of effervescent tablet for the treatment of female vagina and its production and use | |
| CN1424040A (en) | Medicine against human papilloma virus | |
| CN106581172B (en) | Medicine for preventing and treating mycotic vaginitis, trichomonas vaginitis and senile vaginitis and preparation method thereof | |
| CN1840116A (en) | Externally applied medicine for treating skin and mucosa disease caused by human papilloma virus | |
| CN1193779C (en) | Vagina cleaning and antiphlogistic suppository and its preparing method | |
| CN105311328A (en) | Traditional Chinese medicine composition for treating gynecological inflammation and application thereof | |
| CN102485245A (en) | Traditional Chinese medicine composition gelata for treating gynecological inflammations | |
| JP2010195728A (en) | Bowel disease treating agent | |
| CN1192772C (en) | Application of epigallic catechin 3-gallate in treating HPV infection | |
| CN107353416A (en) | A kind of HPV suppresses the preparation method of gel | |
| CN1056774C (en) | Keyoulin sterilizing bactericide | |
| CN1193777C (en) | Chinese medicine for curing cold by omphalotherapy and its preparing process | |
| CN1220515C (en) | Medicine for treating throat disease | |
| CN1771989A (en) | Compound prepn for treating women's inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 |